Scientist.com reaches 10 million human samples in drug research

In a testament to its growing impact on preclinical drug research, Scientist.com, the leading online R&D marketplace for the biopharmaceutical industry, has successfully sourced over 10 million human biological samples through its platform. Since 2015, Scientist.com has been dedicated to connecting biopharma researchers in need of human biosamples for their research studies with a global network of sample providers and biobanks.

"Surpassing 10 million plus samples sourced through the platform is a remarkable achievement that further validates the level of trust our clients and suppliers have in us as well as the due diligence we undertake," stated Matt McLoughlin, Sr. VP of Compliance & Categories at Scientist.com. "Seeing how we have supported and impacted drug discovery and development across the industry strengthens our resolve of helping cure all diseases by 2050."

Human biospecimens play an important role across the entire drug discovery research pipeline, serving as invaluable resources for target discovery, target validation, lead optimization, translational research and clinical development. To mitigate risks associated with sourcing human samples, Scientist.com introduced the award-winning compliance platform, COMPLi®, in 2015. COMPLi minimizes risks through a comprehensive, proprietary due diligence process conducted on all providers offering human biological samples and all users requesting samples for scientific research.

Access exclusive insights from leading pharmaceutical companies, researchers and sample providers on the current landscape of sourcing human biological samples (HBS) for research by downloading Scientist.com's 2023 HBS Report: "Trends and Best Practices in HBS sourcing for R&D"